Nuance 发表于 2025-3-25 05:29:04

http://reply.papertrans.cn/32/3187/318638/318638_21.png

Fulminate 发表于 2025-3-25 08:10:22

http://reply.papertrans.cn/32/3187/318638/318638_22.png

关心 发表于 2025-3-25 12:22:51

http://reply.papertrans.cn/32/3187/318638/318638_23.png

GAVEL 发表于 2025-3-25 16:27:04

Book 2018ble laboratory protocols, and tips on troubleshooting and avoiding known pitfalls...Authoritative and cutting-edge, .Exon Skipping and Inclusion Therapies: Methods and Protocols .aims to help researchers initiate the development of next-generation therapies. .

轿车 发表于 2025-3-25 21:55:15

http://reply.papertrans.cn/32/3187/318638/318638_25.png

laxative 发表于 2025-3-26 02:21:54

http://reply.papertrans.cn/32/3187/318638/318638_26.png

可触知 发表于 2025-3-26 05:31:09

http://reply.papertrans.cn/32/3187/318638/318638_27.png

Conquest 发表于 2025-3-26 08:57:14

Interlocking Socio-Technical Worlds, Food and Drug Agency (FDA) in December of 2016. Here we briefly review the pharmacological relevance of the drug, clinical trials, toxicity, and future directions following the approval of nusinersen.

陈腐思想 发表于 2025-3-26 13:20:24

http://reply.papertrans.cn/32/3187/318638/318638_29.png

ethereal 发表于 2025-3-26 18:05:49

Nusinersen in the Treatment of Spinal Muscular Atrophy Food and Drug Agency (FDA) in December of 2016. Here we briefly review the pharmacological relevance of the drug, clinical trials, toxicity, and future directions following the approval of nusinersen.
页: 1 2 [3] 4 5 6
查看完整版本: Titlebook: Exon Skipping and Inclusion Therapies; Methods and Protocol Toshifumi Yokota,Rika Maruyama Book 2018 Springer Science+Business Media, LLC,